N/A N=150 Methods Project 4: Clinical Trial
Smoker
Primary: Smoke-free Days — 14.5; 0; 0 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=25 Nicotine Pharmacokinetic Study of Heated Tobacco and Heated Herbal Products
Healthy Volunteers
Primary: Nicotine Cmax — 13.00; 12.97; 6.00; 6.87 ng/mL
N/A N=60 Pharmacokinetic and Subjective Effects of Heated Tobacco Products
Tobacco Use
Primary: Baseline-adjusted Plasma Nicotine Concentration Pharmacokinetic (PK) Parameters [Cmax] Assessment — 6.426; 7.953; 8.288; 7.993 ng/mL
Early Phase 1 N=34 Nicotine Reinforcement and Aversion in Young Adult Light Smokers
Nicotine Addiction
Primary: DEQ - Pleasurable — 2.14; 2.05; 1.98; 2.37 score on a scale
N/A N=40 Acute Effects of Cigarette Packaging and Charcoal Filtration on Perceptions, Use Behaviors, and Harm Exposure
Smoking Behaviors
Primary: Number of Puffs Taken (Video-scored Smoking Behavior Outcome 1) — 15.8; 16.7; 19.1; 19.6 puffs
N/A N=10 IQOS (Non-Cigarette Tobacco Product) Pilot Study
Smoking · Tobacco Use
Primary: Number of Participants Who Prefer IQOS — 7 Participants
N/A N=36 Nicotine Pharmacokinetics Following Use of the P4M3 Gen 2.0 E-Cigarette Compared to Smoking Cigarettes
Nicotine Vaping · Nicotine · Vaping
Primary: Background-corrected Maximum Plasma Concentration [Cmax] — 2.934; 3.365; 17.49 (ng/mL)
N/A N=238 Very-Low Nicotine Cigarettes and Non-Daily Smokers
Smoking
Primary: Change in Cigarette Consumption — -1.6; -0.05 cigarettes per day — p=<0.001
N/A N=5 Effects of Smoking State on Decision Making
Behavior
Primary: Effort Based Decision Making — 29.5; 18.3 high effort selections
N/A N=450 E-Cigarette Effects on Markers of Cardiovascular and Pulmonary Disease
Tobacco Use · E-Cigarette Use · Cardiovascular Diseases
Primary: Brachial Artery Flow-Mediated Dilation (FMD)- Pre Challenge — 4.25; 4.89; 5.31 Percent change from resting diameter — p=.494
N/A N=1,236 A Test of Short and Long Term Naturalistic Outcomes of Smokers Who Sample Smokeless Tobacco
Smoking · Smoking Cessation
Primary: Quit Attempts and Abstinence — 25.7; 30.8; 19.8; 25.6 percentage of participants
N/A N=24 A Randomised, Cross-Over, Nicotine Pharmacokinetic and Pharmacodynamic Study of Heated Tobacco Products Compared to Combustible Cigarettes
Healthy Volunteers
Primary: Nicotine Cmax — 10.500; 7.539; 8.191; 21.680 ng/mL
N/A N=60 Smoking Topography and Harm Exposure in Menthol Cigarettes
Cigarette Smoking Toxicity
Primary: Smoking Topography- Puff Volume — 518; 661; 650; 620 mL
N/A N=139 Cigarette Smoking Among Young Adults
Cigarette Smoking · Smoking Behaviors
Primary: Puff Topography — 1108; 1045.2; 1084.6 mL
N/A N=36 Palatability of Experimental Cigarettes - Study 2
Smoking
Primary: Change in UrineTotal Nicotine Equivalent (TNE) Between Baseline and Week 1 — -16.2; -7.6; 1.3 nmols/ml
N/A N=326 Low Nicotine Content Cigarettes in Vulnerable Populations: Women of Reproductive Age
Tobacco Use Disorder
Primary: Number of Cigarettes Smoked Per Day — 22.54; 14.32; 11.76; 7.63 cigarettes per day
Early Phase 1 N=23 Nicotine Delivery Rate and Its Abuse Potential: Impact of Menthol
Nicotine Dependence
Primary: Peak Changes on Items of the Drug Effects Questionnaire (DEQ) - Stimulatory Effects — 7.03; 37.48; 41.91; 28.22 score on a scale
Phase 4 N=96 Combination Nicotine Replacement for Alcoholic Smokers
Smoking · Alcoholism
Primary: 6 Month Smoking Abstinence — 20; 12 percentage of participants abstinent
N/A N=31 Nicotine Pharmacokinetics and Subjective Effects of Nicotine Pouch 1.0 Compared to Velo® Ice Cool and Zyn® Cool Mint Mini Dry in Healthy Smokers
Smoking · Nicotine
Primary: Background-corrected Maximum Plasma Concentration [Cmax] — 8.109; 11.48; 2.629; 3.464 ng/mL
N/A N=22 Assessment of Two New Electronic Cigarettes in Cigarette Smokers
Electronic Cigarettes
Primary: Change in Plasma Nicotine — 7.62; 10.65; 18.31; 7.19 ng/ml
N/A N=1,257 Effects of FDA Authorized Smokeless Tobacco Claims Among US Adults Who Smoke Cigarettes
Tobacco Product Beliefs and Use
Primary: General Relative Harm Perception — 3.04; 2.76; 2.84; 3.19 score on a scale
N/A N=3,125 Nonsmokers Helping Smokers Quit
Smoking Cessation
Primary: Number of Participants Reporting 30-day Abstinence — 203; 222; 135 Participants
Phase 2 N=232 UW Withdraw From Tobacco Study
Tobacco Dependence
Primary: Change in Total Score on Wisconsin Smoking Withdrawal Scale2 Long (WSWS2-L) — 2.64; 2.36; 2.29; 2.69 score on a scale
Phase 3 N=31 Project Q Pilot: Smoking Cessation for Light Smokers
Tobacco Use Cessation
Primary: Number of Participants With Completion of at Least 2 Study Visits — 10; 7; 1 Participants
N/A N=60 Product Use and Adaptation, Safety and Tolerability of P3P in Adult Healthy Smokers Switching to it
Pharmacokinetics
Primary: Plasma Nicotine Concentration-time Profile — 0.563; 0.563; 0.928; 1.02 ng/ml
N/A N=24 Smokers' Response to Nicotine Dependence Genotyping
Cigarette Smoking · Nicotine Dependence
Primary: Change in Baseline Smoking Abstinence at 6 and 10 Weeks After Genotyping Results — 1; 0; 7; 11 Participants
N/A N=22 Comparative Abuse Liability Among African American and White Smokers
Tobacco Use Disorder
Primary: Nicotine Delivery — 14.13; 6.79; 9.15 ng/mL — p=0.002
N/A N=37 Cigarette Smoking Decision Study
Tobacco Smoking
Primary: Demand Intensity as Assessed by a Behavioral Economic Demand Curve — 4.709677419; 2.580645161 puff bouts
N/A N=30 Switching to Potential Reduced Exposure Products in Adult Smokers
Tobacco Use Disorder · Oral Nicotine Pouch Use · Smoking Behaviors
Primary: Number of Cigarettes Smoked Per Day (Log-transformed) — 2.0; 1.8 number of cigarettes smoked
N/A N=24 A Randomised, Cross-over, Relative Bioavailability Study of Nicotine Delivery and Nicotine Extraction From Oral Products
Healthy Volunteers
Primary: Nicotine Cmax — 5.154; 7.856; 9.553; 12.51 ng/mL